<DOC>
	<DOCNO>NCT00283634</DOCNO>
	<brief_summary>Tarceva , orally available small molecule , demonstrate potent activity tumor model human . This randomized , open-label phase 2 study Tarceva alone Tarceva plus VELCADE design primarily determine objective tumor response rate treatments patient Stage IIIB Stage IV non-small cell lung cancer ( NSCLC ) refractory relapse front-line chemotherapy .</brief_summary>
	<brief_title>A Study Tarceva Use Patients With Relapsed Refractory Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 ) Relapsed refractory , Stage IIIB Stage IV NSCLC histologially cytologically confirm . 2 ) One prior line conventional cytotoxic chemotherapy . 3 ) Documented progressive disease ( PD ) since last prior therapy determine investigator . 4 ) 18 y/o old . 5 ) Have measurable disease RECIST . 6 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 7 ) Life expectancy great 3 mo date enrollment . 8 ) Female patient either postmenopausal , surgically sterilize willing use acceptable method birth control . 9 ) Male pateint agree use acceptable method birth control study treatment . 10 ) Provide write informed consent conduct studyrelated procedure . 11 ) Willing able comply protocol requirement . 1 ) Previous treatment w/VELCADE . 2 ) Preexisting interstitial lung disease . 3 ) Peripheral neuropathy Grade 2 great . 4 ) Diarrhea vomit great Grade 1 intensity whether absence presence antidiarrheal and/or antiemetic therapy . 5 ) Chemotherapy , radiation therapy , treatment wtih monoclonal Antibodies , major surgery w/in 4 wks prior enrollment . 6 ) Documented great 10 % WT loss 6 wks . prior enrollment . 7 ) Inadequate organ function screen per laboratory value . 8 ) Myocardial infarction w/in 6 month prior enrollment . 9 ) Brain metastasis . 10 ) Any malignancy NSCLC occur w/in 5 year enrollment exception basal cell carcinoma sin , carcinoma situ cervix . 11 ) Hx allergic reaction compound contain boron mannitol . 12 ) Known human immunodeficiency virus ( HIV ) + hepatitis B . 13 ) Poorly control hypertension , diabetes mellitus , pyschiatric illness . 14 ) Pregnant breastfeed woman . Confirmation patient pregnant must establish negative serum ( BhCG ) .15 ) Currently enrol another clinical research study receive investigational agent w/in 4 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>